اشترك بالحزمة الذهبية واحصل على وصول غير محدود شمرا أكاديميا
تسجيل مستخدم جديدNeurological Consequences of COVID-19 Infection
94
0
0.0
(
0
)
اسأل ChatGPT حول البحث
ﻻ يوجد ملخص باللغة العربية
COVID-19 infections have well described systemic manifestations, especially respiratory problems. There are currently no specific treatments or vaccines against the current strain. With higher case numbers, a range of neurological symptoms are becoming apparent. The mechanisms responsible for these are not well defined, other than those related to hypoxia and microthrombi. We speculate that sustained systemic immune activation seen with SARS-CoV-2 may also cause secondary autoimmune activation in the CNS. Patients with chronic neurological diseases may be at higher risk because of chronic secondary respiratory disease and potentially poor nutritional status. Here, we review the impact of COVID-19 on people with chronic neurological diseases and potential mechanisms. We believe special attention to protecting people with neurodegenerative disease is warranted. We are concerned about a possible delayed pandemic in the form of an increased burden of neurodegenerative disease after acceleration of pathology by systemic COVID-19 infections.
قيم البحث
اقرأ أيضاً
The titled subject has attracted much interest. Here we summarize the substantial results obtained by a physical model of protein evolution based on hydropathic domain dynamics. In a recent Letter eighteen biologists suggested that the titled subject
should be studied in a way inclusive of broad expertise (1). There is an even broader view that has been developed over several decades by physicists (2,3). This view is based on analyzing amino acid sequences of proteins. These sequences are now available on-line at Uniprot, and represent a treasure-trove of data (4).
Many countries have passed their first COVID-19 epidemic peak. Traditional epidemiological models describe this as a result of non-pharmaceutical interventions that pushed the growth rate below the recovery rate. In this new phase of the pandemic man
y countries show an almost linear growth of confirmed cases for extended time-periods. This new containment regime is hard to explain by traditional models where infection numbers either grow explosively until herd immunity is reached, or the epidemic is completely suppressed (zero new cases). Here we offer an explanation of this puzzling observation based on the structure of contact networks. We show that for any given transmission rate there exists a critical number of social contacts, $D_c$, below which linear growth and low infection prevalence must occur. Above $D_c$ traditional epidemiological dynamics takes place, as e.g. in SIR-type models. When calibrating our corresponding model to empirical estimates of the transmission rate and the number of days being contagious, we find $D_csim 7.2$. Assuming realistic contact networks with a degree of about 5, and assuming that lockdown measures would reduce that to household-size (about 2.5), we reproduce actual infection curves with a remarkable precision, without fitting or fine-tuning of parameters. In particular we compare the US and Austria, as examples for one country that initially did not impose measures and one that responded with a severe lockdown early on. Our findings question the applicability of standard compartmental models to describe the COVID-19 containment phase. The probability to observe linear growth in these is practically zero.
Patients infected with SARS-CoV-2 show a wide spectrum of clinical manifestations ranging from mild febrile illness and cough up to acute respiratory distress syndrome, multiple organ failure and death. Data from patients with severe clinical manifes
tations compared to patients with mild symptoms indicate that highly dysregulated exuberant inflammatory responses correlate with severity of disease and lethality. Significantly elevated cytokine levels, i.e. cytokine storm, seem to play a central role in severity and lethality in COVID-19. We have previously shown that excessive cytokine release induced by highly pathogenic avian H5N1 influenza A virus was reduced by application of proteasome inhibitors. In the present study we present experimental data of a central cellular pro-inflammatory signal pathways, NF-kappaB, in the context of published clinical data from COVID-19 patients and develop a hypothesis for a therapeutic approach aiming at the simultaneous inhibition of whole cascades of pro-inflammatory cytokines and chemokines via blocking the nuclear translocation of NF-kappaB by proteasome inhibitors. The simultaneous inhibition of multiple cytokines/chemokines using clinically approved proteasome inhibitors is expected to have a higher therapeutic potential compared to single target approaches to prevent cascade (i.e. triggering, synergistic, and redundant) effects of multiple induced cytokines and may provide an additional therapeutic option to be explored for treatment of critical stage COVID-19 patients.
We consider the recent surge of information on the potential benefits of acid-suppression drugs in the context of COVID-19, with an eye on the variability (and confusion) across the reported findings--at least as regards the popular antacid famotidin
e. The inconsistencies reflect contradictory conclusions from independent clinical-based studies that took roughly similar approaches, in terms of experimental design (retrospective, cohort-based, etc.) and statistical analyses (propensity-score matching and stratification, etc.). The confusion has significant ramifications in choosing therapeutic interventions: e.g., do potential benefits of famotidine indicate its use in a particular COVID-19 case? Beyond this pressing therapeutic issue, conflicting information on famotidine must be resolved before its integration in ontological and knowledge graph-based frameworks, which in turn are useful in drug repurposing efforts. To begin systematically structuring the rapidly accumulating information, in the hopes of clarifying and reconciling the discrepancies, we consider the contradictory information along three proposed axes: (1) a context-of-disease axis, (2) a degree-of-[therapeutic]-benefit axis, and (3) a mechanism-of-action axis. We suspect that incongruencies in how these axes have been (implicitly) treated in past studies has led to the contradictory indications for famotidine and COVID-19. We also trace the evolution of information on acid-suppression agents as regards the transmission, severity, and mortality of COVID-19, given the many literature reports that have accumulated. By grouping the studies conceptually and thematically, we identify three eras in the progression of our understanding of famotidine and COVID-19. Harmonizing these findings is a key goal for both clinical standards-of-care (COVID and beyond) as well as ontological and knowledge graph-based approaches.
Some ideas are presented about the physical motivation of the apparent capacity of generalized logistic equations to describe the outbreak of the COVID-19 infection, and in general of quite many other epidemics. The main focuses here are: the complex
, possibly fractal, structure of the locus describing the contagion event set; what can be learnt from the models of trophic webs with herd behaviour.
سجل دخول لتتمكن من نشر تعليقات
التعليقات
جاري جلب التعليقات
سجل دخول لتتمكن من متابعة معايير البحث التي قمت باختيارها
